The Danaher Corporation (DHR) experiences a mixed bag of investment activity. Certain entities like NorthRock Partners LLC and Focus Partners Wealth have increased their shareholds in the Corporation. In contrast, Pathstone Holdings LLC, Lazard Asset Management LLC and others sold off parts of their stake. Ken Fisher, Charles Akre and John Neff have picked DHR as a stock with massive potential growth.
Following the 2025 Q1 Earnings call, it has been noted that Danaher impressed with their performance in the Bioprocessing category. However, there is a critique of DHR with Jim Cramer calling out the CEO to perform better, adding that he’s 'extremely disappointed' with the Corporation, and asking for the CEO to 'step up or step aside'.
Despite in-line guidance, the stock fell in Q4 causing worry among the investors. Conversely, optimistic next quarter sales guidance has been released post their Q1 Sales surprise. Danaher benefits from switching costs and is among the top healthcare stocks with huge upside potential. The company recently announced an 18.5% dividend increase.
Danaher Corporation DHR News Analytics from Mon, 23 Dec 2024 08:00:00 GMT to Sat, 17 May 2025 11:42:16 GMT - Rating 5 - Innovation 3 - Information 8 - Rumor 2
